|
|
Volumn 27, Issue 6, 1998, Pages 1413-1414
|
|
Editorial response: Randomized trial of lipid-based amphotericin B for invasive aspergillosis in neutropenic hosts is an important step forward
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
AMPHOTERICIN B LIPID COMPLEX;
FLUCYTOSINE;
AMPHOTERICIN B;
ANTIFUNGAL AGENT;
DRUG CARRIER;
LIPOSOME;
ACUTE LEUKEMIA;
ANTIFUNGAL ACTIVITY;
ASPERGILLOSIS;
BONE MARROW DEPRESSION;
BRONCHOSPASM;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DOSE RESPONSE;
DRUG EFFICACY;
DRUG FORMULATION;
EDITORIAL;
HUMAN;
HYPOTENSION;
NEPHROTOXICITY;
NEUTROPENIA;
PRIORITY JOURNAL;
RANDOMIZED CONTROLLED TRIAL;
MORTALITY;
NOTE;
SURVIVAL;
TREATMENT OUTCOME;
AMPHOTERICIN B;
ANTIBIOTICS, ANTIFUNGAL;
ASPERGILLOSIS;
DRUG CARRIERS;
HUMANS;
LIPOSOMES;
NEUTROPENIA;
RANDOMIZED CONTROLLED TRIALS;
SURVIVAL ANALYSIS;
TREATMENT OUTCOME;
|
|
EID: 0032239256
PISSN: 10584838
EISSN: None
Source Type: Journal
DOI: 10.1086/515034 Document Type: Editorial |
|
Times cited : (4)
|
|
References (8)
|
